Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Astellas Pharma's share price for the quarter that ended in Mar. 2026 was $16.15. Astellas Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1,791 Mil. Therefore, Astellas Pharma's market cap for the quarter that ended in Mar. 2026 was $28,933 Mil.
Astellas Pharma's quarterly market cap
increased
from Sep. 2025 ($19,882 Mil) to Dec. 2025 ($23,593 Mil) and
increased
from Dec. 2025 ($23,593 Mil) to Mar. 2026 ($28,933 Mil).
Astellas Pharma's annual market cap
declined
from Mar. 2024 ($20,020 Mil) to Mar. 2025 ($17,456 Mil) but then
increased
from Mar. 2025 ($17,456 Mil) to Mar. 2026 ($28,933 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Astellas Pharma's Enterprise Value for Today is $24,717 Mil.
Astellas Pharma (OTCPK:ALPMF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Astellas Pharma Market Cap Related Terms
Astellas Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Astellas Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Astellas Pharma's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (ALPMF) has a Market Cap of $23,938 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Astellas Pharma and its competitors. According to the industry distribution chart, Astellas Pharma ranks #29 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 2.8%.
Is Astellas Pharma's Market Cap too high?
Astellas Pharma's current Market Cap is $23,938 Mil. The Drug Manufacturers industry median Market Cap is 206.50. Astellas Pharma's value of $23,938 Mil is 11492.4% above this industry median. Based on the distribution chart, Astellas Pharma ranks #29 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #29 out of 1023 companies for Market Cap. This places Astellas Pharma in the top 3% of its industry — outperforming the majority of peers. The industry median Market Cap is 206.50. Astellas Pharma's value of $23,938 Mil is 11492.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.50, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current Market Cap of $23,938 Mil is 11492.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current Market Cap is $23,938 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.18, compared to a current price of $12.85 — trading 9.4% below its estimated fair value. The current Market Cap is $23,938 Mil and 11492.4% above the Drug Manufacturers industry median of 206.50. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Market Cap is $23,938 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $12.85 is trading 9.4% below its estimated GF Value™ of $14.18.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
Market Cap: $23,938 Mil
GF Value™: $14.18 vs. price of $12.85 (9.4% below fair value)
Industry Position: 11492.4% above the Drug Manufacturers median (#29 of 1023)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
